Form 4: Regeneron CFO Christopher R. Fenimore Reports Stock Transactions

Regeneron's CFO, Christopher R. Fenimore, reported the acquisition of restricted stock and stock options, as well as the disposal of shares to cover tax obligations.

Summary

• Christopher R. Fenimore, the SVP Finance & CFO of Regeneron Pharmaceuticals, Inc., reported several transactions involving the company's stock.
• On December 6, 2024, Mr. Fenimore acquired 2,591 shares of common stock as a restricted stock award, which will vest in two equal installments on December 6, 2026 and December 6, 2028.
• Also on December 6, 2024, he was granted a non-qualified stock option for 9,979 shares, which vests in four equal annual installments starting one year after the grant date.
• On December 9, 2024, Mr. Fenimore disposed of 1,140 shares of common stock at a price of $787 per share.
• Following these transactions, Mr. Fenimore directly owns 16,756 shares of common stock.
• He also indirectly owns 1,515 shares through a 401(k) plan, 1,897 shares through a trust for his spouse, and 25 shares each through trusts for his daughter and son.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices and insider trading reporting. The acquisition of stock and options is positive, while the disposal is likely for tax purposes and not a major concern.

Positives

• The acquisition of restricted stock and stock options indicates management's long-term commitment to the company.
• The vesting schedule of the restricted stock aligns with a long-term incentive plan.

Negatives

• The disposal of 1,140 shares, while likely for tax purposes, could be perceived negatively by some investors.

Risks

• The stock transactions are subject to market fluctuations and could impact the value of Mr. Fenimore's holdings.
• Changes in the company's performance could affect the vesting and value of the stock options and restricted stock.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Stock option and restricted stock grants are common forms of executive compensation in the pharmaceutical industry, used to align management's interests with those of shareholders.
• The vesting schedules for the restricted stock and stock options are typical for long-term incentive plans.
• The disposal of shares to cover tax obligations is a common practice among executives who receive equity compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholder sentiment, but are generally considered routine.
• The vesting of stock options and restricted stock aligns management's interests with long-term shareholder value.

Key Dates

Keywords

Regeneron, Stock Options, Restricted Stock, Form 4, Insider Trading, Christopher R. Fenimore, Executive Compensation, Equity Securities